EXPERIENCE FAST RDS SUCCESS

Each year, more babies are treated for RDS with CUROSURF® (poractant alfa) Intratracheal Suspension than any other surfactant.1

Low volume for efficient administration

CUROSURF delivers more surfactant in a smaller overall volume for efficient instillation that may help to minimize complications.2-6 LEARN MORE

Clinical studies have not established that lower volume results in superior efficacy or safety based on clinically relevant end points.

Rapid onset of action

CUROSURF goes to work fast, improving oxygenation within 5 minutes.7,8 LEARN MORE

Physiological end points (eg, faster reduction in FiO2) have not been proven to impact key clinical outcomes such as mortality due to RDS.

Sustained results with fewer doses

In clinical studies, most infants required only one dose, which may reduce complications associated with reintubation and subsequent mechanical ventilation.9,13 LEARN MORE

Clinical studies have not established that fewer doses or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

Comprehensive support with the CUROSURF Experience Program

Experience a smooth process evaluating CUROSURF in your NICU with a comprehensive support program from Chiesi USA. LEARN MORE